Skip to main content Skip to navigation
PE Mouse Anti-Human Cytokeratin
Product Details
Down Arrow Up Arrow

Cytokeratin-7/-8; CK-7/CK-8;
Mouse BALB/c IgG2a
Human HT29 colorectal carcinoma cell line
Intracellular staining (flow cytometry)
6 μg/mL
20 μL
Phosphate buffered saline with gelatin and 0.1% sodium azide.

Preparation And Storage

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

347204 Rev. 1
Antibody Details
Down Arrow Up Arrow

The Anti-Cytokeratin antibody, clone CAM 5.2, is derived from the hybridization of P3/NS-1/1-Ag4-1 mouse myeloma cells with spleen cells from BALB/c mice immunized with the human colorectal carcinoma cell line HT29.

The Anti-Cytokeratin antibody has a primary reactivity with human cytokeratin proteins that correspond to Moll’s peptide #7 (cytokeratin 7) and Moll’s peptide #8 (cytokeratin 8), 54 and 53 kilodaltons (kDa), respectively.

347204 Rev. 1
Format Details
Down Arrow Up Arrow
R-Phycoerythrin (PE), is part of the BD family of Phycobiliprotein dyes. This fluorochrome is a multimeric fluorescent phycobiliprotein with excitation maximum (Ex Max) of 496 nm and 566 nm and an emission maximum (Em Max) at 576 nm. PE is designed to be excited by the Blue (488 nm), Green (532 nm) and Yellow-Green (561 nm) lasers and detected using an optical filter centered near 575 nm (e.g., a 575/26-nm bandpass filter). As PE is excited by multiple lasers, this can result in cross-laser excitation and fluorescence spillover on instruments with various combinations of Blue, Green, and Yellow-Green lasers. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
Yellow-Green 488 nm, 532 nm, 561 nm
496 nm, 566 nm
576 nm
347204 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "347204" on CiteAb

Development References (8)

  1. Battifora H. Diagnostic uses of antibodies to keratins: A review and immunohistochemical comparison of seven monoclonal and three polyclonal antibodies. In: Fenoglio-Preiser C, Wolff M, Rilke F, ed. Progress in Surgical Pathology. 1988:1-15.
  2. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
  3. Clinical and Laboratory Standards Institute. 2005. (Biology).
  4. Cooper D, Schermer A, Sun TT. Biology of disease classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications and limitations. Lab Invest. 1985; 52:243-256. (Biology). View Reference
  5. Johnson A, Cavallin-Stahl E, Akerman M. Flow cytometric light chain analysis of peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Br J Cancer. 1985; 52(2):159-168. (Biology). View Reference
  6. Makin C, Bobrow L, Bodmer W. Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol. 1984; 37(9):975-983. (Biology). View Reference
  7. Moll R, Franke W, Schiller D, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors, and cultured cells. Cell. 1982; 31:11-24. (Biology). View Reference
  8. Smedts F, Ramaekers F, Robben H, et al. Changing patterns of keratin expression during progression of cervical intraepithelial neoplasia. Am J Pathol. 1990; 136(3):657-668. (Biology). View Reference
View All (8) View Less
347204 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. 


Although not required, these products are manufactured in accordance with Good Manufacturing Practices.